microRNA-622 acts as a tumor suppressor in hepatocellular carcinoma

microRNAs (miRNAs) are important regulators of tumor development and progression. In this study, we aimed to explore the expression and role of miR-622 in hepatocellular carcinoma (HCC). We found that miR-622 was significantly downregulated in human HCC specimens compared to adjacent noncancerous liver tissues. miR-622 downregulation was significantly associated with aggressive parameters and poor prognosis in HCC. Enforced expression of miR-622 significantly decreased the proliferation and colony formation and induced apoptosis of HCC cells. In vivo studies demonstrated that miR-622 overexpression retarded the growth of HCC xenograft tumors. Bioinformatic analysis and luciferase reporter assays revealed that miR-622 directly targeted the 3′-untranslated region (UTR) of mitogen-activated protein 4 kinase 4 (MAP4K4) mRNA. Ectopic expression of miR-622 led to a significant reduction of MAP4K4 expression in HCC cells and xenograft tumors. Overexpression of MAP4K4 partially restored cell proliferation and colony formation and reversed the induction of apoptosis in miR-622-overexpressing HCC cells. Inhibition of JNK and NF-κB signaling phenocopied the anticancer effects of miR-622 on HCC cells. Taken together, miR-622 acts as a tumor suppressor in HCC and restoration of miR-622 may provide therapeutic benefits in the treatment of HCC.

[1]  Lei Shan,et al.  MicroRNA-377 Suppresses Cell Proliferation and Invasion by Inhibiting TIAM1 Expression in Hepatocellular Carcinoma , 2015, PloS one.

[2]  Haiming Wei,et al.  MicroRNA-362-5p promotes tumor growth and metastasis by targeting CYLD in hepatocellular carcinoma. , 2015, Cancer letters.

[3]  Yang Zhang,et al.  microRNA-146a inhibits cancer metastasis by downregulating VEGF through dual pathways in hepatocellular carcinoma , 2015, Molecular Cancer.

[4]  Ying-jian Liang,et al.  Reciprocal activation between ATPase inhibitory factor 1 and NF‐κB drives hepatocellular carcinoma angiogenesis and metastasis , 2014, Hepatology.

[5]  W. Schiemann,et al.  Therapeutic opportunities for targeting microRNAs in cancer , 2014, Molecular and Cellular Therapies.

[6]  J. Luk,et al.  Anti-Cadherin-17 Antibody Modulates Beta-Catenin Signaling and Tumorigenicity of Hepatocellular Carcinoma , 2013, PloS one.

[7]  Y. Niu,et al.  miRNA-141, Downregulated in Pancreatic Cancer, Inhibits Cell Proliferation and Invasion by Directly Targeting MAP4K4 , 2013, Molecular Cancer Therapeutics.

[8]  Xiao-Jun Feng,et al.  Expression and prognostic significance of MAP4K4 in lung adenocarcinoma. , 2012, Pathology, research and practice.

[9]  H. Hermeking,et al.  MicroRNAs in the p53 network: micromanagement of tumour suppression , 2012, Nature Reviews Cancer.

[10]  H. Willenbrock,et al.  MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma , 2012, Modern Pathology.

[11]  D. Haas-Kogan,et al.  Hepatocellular carcinoma: natural history, current management, and emerging tools , 2012, Biologics : targets & therapy.

[12]  M. Imamura,et al.  Recent trend of clinical features in patients with hepatocellular carcinoma , 2012, Hepatology research : the official journal of the Japan Society of Hepatology.

[13]  C. Boland,et al.  Colorectal Cancers with Microsatellite Instability Display Unique miRNA Profiles , 2011, Clinical Cancer Research.

[14]  Li Zhang,et al.  Down-regulation of miR-622 in gastric cancer promotes cellular invasion and tumor metastasis by targeting ING1 gene. , 2011, World journal of gastroenterology.

[15]  D. Greiner,et al.  The role of JNK in the development of hepatocellular carcinoma. , 2011, Genes & development.

[16]  Ju-Seog Lee,et al.  Inhibition of the proliferation and invasion of hepatocellular carcinoma cells by lipocalin 2 through blockade of JNK and PI3K/Akt signaling. , 2011, International journal of oncology.

[17]  Ming-hua Zhu,et al.  ShRNA-Targeted MAP4K4 Inhibits Hepatocellular Carcinoma Growth , 2010, Clinical Cancer Research.

[18]  G. Mufti,et al.  A functional assay for microRNA target identification and validation , 2010, Nucleic acids research.

[19]  S. Sanderson,et al.  Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors , 2010, Liver international : official journal of the International Association for the Study of the Liver.

[20]  Junji Furuse,et al.  The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. , 2010, The oncologist.

[21]  B. Wei,et al.  Involvement of NF-kappaB activation in the apoptosis induced by extracellular adenosine in human hepatocellular carcinoma HepG2 cells. , 2010, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[22]  P. Boyle,et al.  World Cancer Report 2008 , 2009 .

[23]  Stanley R Hamilton,et al.  Expression of MAP4K4 Is Associated with Worse Prognosis in Patients with Stage II Pancreatic Ductal Adenocarcinoma , 2008, Clinical Cancer Research.

[24]  Yingyao Zhou,et al.  A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[25]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[26]  B. Stewart,et al.  World Cancer Report , 2003 .

[27]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[28]  T. Jiang,et al.  miR-622 suppresses proliferation, invasion and migration by directly targeting activating transcription factor 2 in glioma cells , 2014, Journal of Neuro-Oncology.

[29]  Yiguo Jiang,et al.  MicroRNA-622 functions as a tumor suppressor by targeting K-Ras and enhancing the anticarcinogenic effect of resveratrol. , 2012, Carcinogenesis.

[30]  Leslie H. Sobin,et al.  TNM Classification of Malignant Tumours, 7th Edition , 2009 .

[31]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.